Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

INKEF Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 76
Average round size
The average size of a deal this fund participated in
Portfolio companies 50
Rounds per year 6.33
Lead investments 33
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 8
Key employees 8
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Software
  • Medical
  • Medical Device

In 2010 was created INKEF Capital, which is appeared as VC. The leading representative office of defined VC is situated in the Amsterdam. The company was established in Europe in The Netherlands.

The overall number of key employees were 7.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the INKEF Capital, startups are often financed by Union Square Ventures, Life Sciences Partners, Index Ventures. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Healthinnovations, Gilde Healthcare. In the next rounds fund is usually obtained by Keen Venture Partners, Union Square Ventures, Rabobank.

The top amount of exits for fund were in 2018. The real fund results show that this VC is 48 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this INKEF Capital performs on 15 percentage points less the average number of lead investments. The high activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.

The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Health Care, Biopharma. For fund there is a match between the location of its establishment and the land of its numerous investments - The Netherlands. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight NMD Pharma, Rainier Therapeutics, Shapeways.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of INKEF Capital:
Typical Co-investors
INKEF Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after INKEF Capital:

Funds with similar focus

Funds from The Netherlands
Funds with similar focus located in The Netherlands:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Cloud Computing
Human Resources
Online Portals
$26M07 Jul 2022 Helsinki, Uusimaa, Finland


$5M06 Jul 2022 -


$94M16 Mar 2022 City of Brussels, Belgium


Information Technology
Retail Technology
$53M15 Mar 2022 Leiden, South Holland, Netherlands

Scenic Biotech

Collaborative Consumption
Life Science
$33M10 Mar 2022 Amsterdam, North Holland, Netherlands

TargED Biopharmaceuticals

Health Care
$46M19 Feb 2022 Utrecht, Utrecht, The Netherlands

AmbAgon Therapeutics

Product Research
$85M06 Jan 2022 San Francisco, California, United States


Health Care
Medical Device
$76M16 Dec 2021 Utrecht, Utrecht, Netherlands


3D Printing
Business/Productivity Software
Multimedia and Design Software
Peer to Peer
$75M30 Sep 2021 New York, New York, United States
Cardior Raises €64M in Series B Funding

– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.

Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives

– Castor, a leading provider of clinical trial software, announced the closing of a $45m Series B financing round.
– The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.
– Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent INKEF Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: